

Special Issue

Long Noncoding RNAs in Brain Diseases

Message from the Guest Editor

Long non-coding RNAs (lncRNAs) are fascinating molecules that shape how our brains work. They do not make proteins, but they control how genes are turned on and off, how neurons grow and connect, and how the brain adapts to changes. When lncRNAs go wrong, they can cause many different brain diseases. For example, in Alzheimer's, Parkinson's, Huntington's, and ALS, lncRNAs affect the buildup of toxic proteins that damage brain cells. In schizophrenia, bipolar disorder, and depression, lncRNAs influence how neurons communicate and respond to stress. In brain cancers such as glioblastoma and medulloblastoma, lncRNAs help tumor cells grow, spread, and resist drugs. In autism and intellectual disabilities, lncRNAs affect how the brain develops and learns. By studying lncRNAs, we can learn more about these conditions and find new ways to diagnose and treat them. We can also try to change the activity of specific lncRNAs that are involved in disease processes and see if we can improve the outcomes. However, there is still much to discover about how lncRNAs work and how to target them safely and effectively.

Guest Editor

Dr. Arun Renganathan

Department of Psychiatry, Washington University in St. Louis, St. Louis, MI 63110, USA

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/193595

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).